Table 1

Patients with anterior uveitis (AU; n = 30): Clinical history and investigations
Female Male Total
Age Mean age (range): 40.7 (19–56) 40.3 (21–69)
Duration Limited ≤ 3 months 9 14 23
Persistent > 3 months 6 1 7
Course Acute (sudden onset and limited duration) 9 10 19
Recurrent (repeated episodes separated by periods of inactivity without treatment ≥3 months in duration) 0 5 5
Chronic (persistent uveitis with relapse in <3 months after discontinuing treatment) 6 0 6
Treatment duration <1 week 2 0 2
1-2 weeks 7 12 19
3-6 weeks 2 2 4
7-12 weeks 0 1 1
Chronic (>12 weeks) 3 0 3
Long term remission 1 0 1
HLA-B27 Negative 8 1 9
Positive 7 14 21
Relative macular thickening Normal (235-259 μm females, 244-272 μm males) 5 3 8
Thickening (≥259 μm females, ≥272 μm males) 9 12 21
Atrophy (≤238 μm in females, ≤243 μm males) 1 0 1
Best corrected visual acuity ≥0.8 11 13 24
0.6-0.7 4 0 4
0.4-0.5 0 1 1
0.2-0.3 0 1 1
AU episode First episode 7 8 15
Several episodes 5 7 12
Chronic 3 0 3
Anterior chamber cells Grade 0, <1 cell 4 3 7
Grade 0.5+, 1–5 cells 1 2 3
Grade 1+, 6–15 cells 7 5 12
Grade 2+, 16–25 cells 3 4 7
Grade 3+, 26–50 cells 0 1 1
Spillover No retrolental cells 13 9 22
1-5 retrolental cells 2 6 8
Systemic symptoms Diagnosed spondyloarthropathy 2 9 11
Joint/ skin/ intestinal/urogenital complaints 4 3 7
Tiredness, morning stiffness/ pain 6 2 8
None 3 1 4
Systemic treatment None 11 8 19 (11)*
Oral prednisolone 2 6 8 (8)*
Immunomodulatory treatment 2 1 3 (2)*
Uveitis in contralateral eye Never uveitis in contralateral eye 6 10 16 (12)*
At least one earlier episode 7 5 12 (9)*
Bilateral uveitis now 2 0 2 (0)*
Contralateral AU last three month Never uveitis 6 10 16
≤ 3 months prior to examination 1 4 5
≥ 3 months prior to examination 8 1 9

* The number of HLA-B27+ patients are given in parentheses.

Wexler et al.

Wexler et al. BMC Ophthalmology 2012 12:30   doi:10.1186/1471-2415-12-30

Open Data